Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EWTXNASDAQ:INDVNASDAQ:IRONNASDAQ:RAPP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEWTXEdgewise Therapeutics$16.91+1.4%$19.32$10.60▼$38.12$1.77B0.321.16 million shs1.43 million shsINDVIndivior$11.98+3.7%$9.75$7.33▼$18.59$1.65B0.93985,869 shs914,871 shsIRONDisc Medicine$49.51-0.3%$47.96$28.25▼$68.73$1.71B0.77344,826 shs202,082 shsRAPPRapport Therapeutics$11.33-1.2%$9.89$6.43▼$29.74$413.52MN/A176,735 shs79,809 shs10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEWTXEdgewise Therapeutics+1.38%+13.95%+8.96%-39.65%-11.05%INDVIndivior+3.72%+3.63%+25.84%+0.67%-32.05%IRONDisc Medicine-0.34%+9.00%+2.02%-11.27%+73.54%RAPPRapport Therapeutics-1.22%+6.69%+13.76%-30.96%+1,132,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEWTXEdgewise Therapeutics2.9784 of 5 stars4.41.00.00.02.83.30.0INDVIndivior3.38 of 5 stars3.63.00.00.02.71.71.9IRONDisc Medicine2.3973 of 5 stars3.51.00.00.04.02.50.0RAPPRapport Therapeutics2.3441 of 5 stars3.52.00.00.02.51.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEWTXEdgewise Therapeutics 2.78Moderate Buy$40.22137.86% UpsideINDVIndivior 3.25Buy$15.0025.21% UpsideIRONDisc Medicine 3.09Buy$93.8089.46% UpsideRAPPRapport Therapeutics 3.00Buy$32.67188.32% UpsideCurrent Analyst Ratings BreakdownLatest RAPP, EWTX, IRON, and INDV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/30/2025EWTXEdgewise TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$41.004/21/2025EWTXEdgewise TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$43.00 ➝ $43.004/8/2025RAPPRapport TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Outperform$28.004/8/2025RAPPRapport TherapeuticsCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMkt Outperform4/3/2025EWTXEdgewise TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$56.00 ➝ $52.004/2/2025EWTXEdgewise TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$51.00 ➝ $51.004/2/2025EWTXEdgewise TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeSector Outperform ➝ Sector Perform$50.00 ➝ $14.003/18/2025IRONDisc MedicineCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$99.00 ➝ $132.003/7/2025EWTXEdgewise TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$50.003/7/2025IRONDisc MedicineMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$85.003/6/2025INDVIndiviorPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$16.00 ➝ $13.00(Data available from 5/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEWTXEdgewise TherapeuticsN/AN/AN/AN/A$4.53 per shareN/AINDVIndivior$1.17B1.41$2.43 per share4.94N/A∞IRONDisc MedicineN/AN/AN/AN/A$14.17 per shareN/ARAPPRapport TherapeuticsN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEWTXEdgewise Therapeutics-$100.16M-$1.45N/AN/AN/AN/A-26.83%-25.67%5/8/2025 (Estimated)INDVIndivior$2M-$0.31N/A7.01N/A-3.96%-241.73%15.09%N/AIRONDisc Medicine-$76.43M-$3.99N/AN/AN/AN/A-25.24%-23.96%5/8/2025 (Estimated)RAPPRapport Therapeutics-$34.79M-$13.84N/AN/AN/AN/AN/AN/A6/2/2025 (Estimated)Latest RAPP, EWTX, IRON, and INDV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025EWTXEdgewise Therapeutics-$0.45N/AN/AN/AN/AN/A5/8/2025Q1 2025IRONDisc Medicine-$0.99N/AN/AN/AN/AN/A4/24/2025Q1 2025INDVIndivior$0.22$0.41+$0.19$0.38$240.13 million$266.00 million3/3/2025Q4 2024EWTXEdgewise Therapeutics-$0.39-$0.42-$0.03-$0.42N/AN/A2/27/2025Q4 2024IRONDisc Medicine-$1.06-$0.98+$0.08-$0.98N/AN/A2/20/2025Q4 2024INDVIndivior$0.32$0.32N/A$0.07$262.35 million$298.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEWTXEdgewise TherapeuticsN/AN/AN/AN/AN/AINDVIndiviorN/AN/AN/AN/AN/AIRONDisc MedicineN/AN/AN/AN/AN/ARAPPRapport TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEWTXEdgewise TherapeuticsN/A26.3526.35INDVIndiviorN/A0.830.65IRONDisc MedicineN/A19.3619.36RAPPRapport TherapeuticsN/A45.9145.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEWTXEdgewise TherapeuticsN/AINDVIndivior60.33%IRONDisc Medicine83.70%RAPPRapport TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipEWTXEdgewise Therapeutics24.11%INDVIndiviorN/AIRONDisc Medicine4.24%RAPPRapport TherapeuticsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEWTXEdgewise Therapeutics60104.77 million71.86 millionOptionableINDVIndivior1,164137.88 millionN/ANot OptionableIRONDisc Medicine3034.57 million28.50 millionNot OptionableRAPPRapport TherapeuticsN/A36.50 millionN/AN/ARAPP, EWTX, IRON, and INDV HeadlinesRecent News About These CompaniesWhy Rapport Therapeutics, Inc.’s (RAPP) Stock Is Up 5.49%May 3 at 5:07 PM | aaii.comMise à disposition du rapport financier annuel 2024April 30 at 11:45 AM | globenewswire.comWhy Rapport Therapeutics, Inc.’s (RAPP) Stock Is Up 7.06%April 29, 2025 | aaii.comRapport Therapeutics (NASDAQ:RAPP) Shares Sold by T. Rowe Price Investment Management Inc.April 29, 2025 | marketbeat.comRapport Therapeutics (RAPP) and Its Rivals Critical ContrastApril 26, 2025 | americanbankingnews.comRapport Therapeutics (NASDAQ:RAPP) Short Interest UpdateApril 22, 2025 | marketbeat.comRapport Therapeutics to Participate in Upcoming Investor ConferencesApril 22, 2025 | globenewswire.comTrv Gp V LLC Invests $126.58 Million in Rapport Therapeutics (NASDAQ:RAPP)April 22, 2025 | marketbeat.comTrv Gp Vi LLC Invests $17.19 Million in Rapport Therapeutics (NASDAQ:RAPP)April 22, 2025 | marketbeat.comMeloni and Trump: An Oval Office Meeting With Rapport and BanterApril 18, 2025 | nytimes.com48,452 Shares in Rapport Therapeutics (NASDAQ:RAPP) Acquired by Norges BankApril 14, 2025 | marketbeat.comJMP Securities Initiates Coverage on Rapport Therapeutics (NASDAQ:RAPP)April 10, 2025 | marketbeat.comCitizens Jmp Begins Coverage on Rapport Therapeutics (NASDAQ:RAPP)April 10, 2025 | marketbeat.comRapport Therapeutics initiated with an Outperform at Citizens JMPApril 9, 2025 | markets.businessinsider.comBuy Rating for Rapport Therapeutics: Promising Precision Therapeutics for CNS DisordersApril 9, 2025 | tipranks.comJMP Securities Initiates Coverage of Rapport Therapeutics (RAPP) with Market Outperform RecommendationApril 9, 2025 | msn.comWhy Rapport Therapeutics, Inc.’s (RAPP) Stock Is Down 14.46%April 3, 2025 | aaii.comRapport Therapeutics: Too Early To Be InterestingMarch 31, 2025 | seekingalpha.comCrédit Agricole Ille-et-Vilaine : Communiqué de mise à disposition du rapport financier 2024March 27, 2025 | globenewswire.comRapport Therapeutics to showcase data at 2025 American Academy of Neurology Annual Meeting in San Diego from April 5-9, 2025March 25, 2025 | pharmabiz.comRapport Therapeutics to present data at 2025 AAN meetingMarch 22, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesCrowdStrike Stock is a Buy as Cyberthreat Environment ExpandsBy Chris Markoch | April 15, 2025View CrowdStrike Stock is a Buy as Cyberthreat Environment ExpandsMedtronic: A Dividend Aristocrat With Stability and InnovationBy Jeffrey Neal Johnson | April 22, 2025View Medtronic: A Dividend Aristocrat With Stability and Innovation3 Energy Stock Winners Even as Oil Prices PlungeBy Chris Markoch | April 11, 2025View 3 Energy Stock Winners Even as Oil Prices PlungeCoca-Cola Stock Looks Refreshing After the Relief Rally By Chris Markoch | April 13, 2025View Coca-Cola Stock Looks Refreshing After the Relief Rally Hidden Gems: 3 Quiet Stocks With Loud PotentialBy Nathan Reiff | April 23, 2025View Hidden Gems: 3 Quiet Stocks With Loud PotentialRAPP, EWTX, IRON, and INDV Company DescriptionsEdgewise Therapeutics NASDAQ:EWTX$16.91 +0.23 (+1.38%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$16.92 +0.01 (+0.06%) As of 05/2/2025 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.Indivior NASDAQ:INDV$11.98 +0.43 (+3.72%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$11.80 -0.18 (-1.49%) As of 05/2/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Disc Medicine NASDAQ:IRON$49.51 -0.17 (-0.34%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$49.52 +0.01 (+0.02%) As of 05/2/2025 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.Rapport Therapeutics NASDAQ:RAPP$11.33 -0.14 (-1.22%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$11.34 +0.02 (+0.13%) As of 05/2/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/28 - 05/02 Amazon Earnings: 2 Reasons to Love It, 1 Reason to Be Cautious Meta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2 Why Spotify Stock Still Has Room to Run in 2025 Is It Time to Load Up on Bond ETFs? Palantir Earnings: 1 Bullish Signal and 1 Area of Concern Roblox Stock Gains Momentum and Can Top $100 in 2025 Visa Q2 Earnings Top Forecasts, Adds $30B Buyback Plan Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
